FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.
What happened
FDA inspected the contract testing laboratory in Hoskote, India, from January 20 to 24, 2025. Investigators found inadequate investigations of out-of-specification results and human-error CAPA, plus many torn or discarded original CGMP documents, including balance and pH printouts; some balance printouts showed test weights different from documented testing. FDA also found hundreds of MassLynx audit-trail entries allowing peak changes and file alterations from January 2022 through January 2025.
What FDA found
The firm did not thoroughly investigate out-of-specification results or unexplained discrepancies, and it used new test results to invalidate OOS results without an adequate root-cause investigation.
21 CFR 211.192The firm did not take effective corrective and preventive action for recurring human errors that drove many laboratory incidents and OOS investigations over three years.
21 CFR 211.192The quality control unit failed to establish or follow adequate written responsibilities and procedures to ensure reliable analytical testing data.
21 CFR 211.22(d)FDA found many torn and discarded original CGMP documents, including analytical balance printouts, pH meter printouts, and method verification records, in the main waste area.
21 CFR 211.22(d)Discarded balance printouts contained test weights different from those documented in testing of raw materials and finished products, including products intended for the U.S. market.
21 CFR 211.22(d)MassLynx audit trails showed hundreds of entries allowing analysts to add, modify, or delete peaks and alter existing files from January 2022 to January 2025.
21 CFR 211.22(d)
What FDA wants
FDA tells Shiva to promptly correct the violations and respond in writing within 15 working days with a retrospective independent review of all OOS and laboratory incident investigations, independent assessments of its investigation, quality-control, documentation, and laboratory systems, and detailed remediation plans. FDA also recommends engaging a qualified CGMP consultant.
Who should pay attention
- drug manufacturers that use Shiva as a contract testing laboratory
- application sponsors relying on Shiva's analytical data
- brands and suppliers whose products were tested at this site
This is a summary. Read the original letter on fda.gov.